AP
ALXN

Arlington Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Arlington Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-59
Closed -$5K – 315
2020
Q1 		$5K Hold
59
– – ﹤0.01% 199
2019
Q4 		$6K Buy
+59
New +$6.31K ﹤0.01% 217
2019
Q1 		– Sell
-59
Closed -$6K – 252
2018
Q4 		$6K Buy
+59
New +$6.97K ﹤0.01% 179

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arlington Partners's ALXN Position: Q2 2020 in Review

Arlington Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 59 shares — an estimated $5K sold.

Arlington Partners first reported a position in ALXN in Q4 2018 and held it in 3 quarters. The position peaked at $6K in Q4 2019. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Arlington Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Arlington Partners sold 59 Alexion Pharmaceuticals shares in Q2 2020, an estimated $5K.
  • Arlington Partners first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Arlington Partners's Alexion Pharmaceuticals position peaked at $6K in Q4 2019.
  • 705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Arlington Partners's 13F filing for Q2 2020, filed 13 Jul 2020.